Join to access to all OVN content. Join for Free

Results for 'change management in healthcare AI'

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Innovation, Expanded access, Early drug access, Cancer, FDA, EMA

Cancer incidence is increasing globally, and while medical innovation significantly impacts patient survival, the drug development process is lengthy, often exceeding 10 years for marketing authorization (MA). France has implemented the ATU (Temporary Authorization for Use) program to facil…

Apr 7th • 12 mins read

Empowering people to drive medical affairs performance with AI
Partner Avatar Envision Pharma Group
Empowering people to drive medical affairs performance with AI

AI in medical affairs, 4Sight approach to AI, empowering medical teams with AI, AI-driven medical affairs performance, enhancing medical affairs through AI, AI integration in healthcare, training for AI adoption, change management in healthcare AI, AI too

Artificial intelligence (AI) is transforming the pharmaceutical industry and continues to be a key topic of discussion in the field. As medical affairs grow more complex, AI can significantly reduce the time required to analyze and extract valuable insights, thereby accelerating the generation of ac…

Aug 14th • 5 mins read

Related Topics

Loading...